BioAge Labs, Inc. (BIOA) AI Stock Analysis

• Market Cap: $499.10M
• Dividend Yield: N/A
• Average Volume (3M): 196.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: N/A
• EPS Growth: -1.89%
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.56
• Shares Outstanding: 35,855,038
• 10 Day Avg. Volume: 197,907
• 30 Day Avg. Volume: 196,830
• PEG Ratio: 0.04
• Price to Book (P/B): 0.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: -0.28
• Enterprise Value/Revenue: -23.74
• Enterprise Value/Gross Profit: -23.74
• Enterprise Value/Ebitda: 1.88
• 1Y Price Target: $13.50
• Price Target Upside: -3.02% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $16.00 ▲(14.94% Upside)

The score is held back primarily by weak financial performance—large losses and substantial cash burn despite modest revenue growth—partially offset by a currently supportive balance sheet. Technically, the stock shows strong upward momentum (above key moving averages and positive MACD), though overbought RSI raises near-term volatility risk. Valuation remains challenged due to unprofitability, while the positive Phase 1 update is a meaningful supportive event.

Positive Factors

Low leverage and sizable equity

Very low debt relative to equity provides structural financial flexibility, reducing near-term refinancing risk and enabling continued R&D spending or strategic partnerships without immediate pressure to cut programs. This supports runway management over the next several quarters.

Positive Phase 1 BGE-102 data

Robust target engagement and CNS penetration materially strengthen the clinical-stage pipeline, improving the probability of downstream programs and partnership interest. Structural clinical progress creates durable pipeline value and a clear near-term catalyst path with more data expected in H1 2026.

Early revenue traction

Sustained double-digit top-line growth from a low base indicates early commercialization progress and product/service uptake. Continued revenue scaling would reduce dependency on external funding and improve long-term cash generation potential if margins expand with scale.

Negative Factors

High cash burn

Persistent large negative operating and free cash flows create a structural funding need that can force dilutive financing or limit strategic optionality. Until revenues scale materially or expenses are reduced, cash burn remains a core constraint on sustainable operations.

Large ongoing losses

Substantial, recurring net losses and negative operating margins reflect an inability to generate profits from current operations. This pressures long-term viability absent sustained revenue growth or material margin improvement and delays any path to self-funded expansion.

Negative ROE and historical equity weakness

Negative returns on equity and historical episodes of negative equity signal reliance on external financing to rebuild capital. Structurally, this raises the likelihood of future dilutive raises and can constrain investor confidence and strategic investments over the medium term.

BioAge Labs, Inc. Business Overview & Revenue Model

Company Description

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

How the Company Makes Money

BioAge Labs, Inc. generates revenue primarily through partnerships and collaborations with pharmaceutical companies, as well as through research grants and funding. The company engages in strategic alliances to co-develop and commercialize its therapeutic candidates, which allows it to share development costs and potential profits. Additionally, BioAge may receive milestone payments and royalties from its partners as its drug candidates progress through clinical trials and, if successful, reach the market. The company may also rely on venture capital investments and public or private offerings to fund its research and development activities.

BioAge Labs, Inc. Financial Statement Overview

Summary

BioAge Labs, Inc. faces significant financial challenges, with no revenue generation and increasing losses impacting profitability. While the balance sheet has improved due to recent financing activities, the company's reliance on external funds and negative cash flows suggest ongoing financial instability. The company needs to address its revenue generation capabilities to improve its financial health.

Income Statement

BioAge Labs, Inc. has not generated any revenue over the past three years, impacting its ability to achieve positive profit margins. The company is experiencing increasing losses, as reflected in the negative EBIT and net income figures. This lack of revenue generation and increasing losses are significant concerns for the company's financial health.

Balance Sheet

The company's debt-to-equity position has improved significantly, transitioning from negative equity to a positive equity position in 2024, driven by increased financing activities. Despite this improvement, the company still carries some debt, which poses a risk. The equity ratio has improved to 90%, indicating a stronger balance sheet, but the company's reliance on external financing remains a concern.

Cash Flow

BioAge Labs, Inc. has been raising substantial funds, as seen from the positive financing cash flow. However, the company is still burning cash, with negative operating and free cash flows. The free cash flow growth rate remains negative, indicating ongoing operational cash challenges. The company's ability to sustain operations relies heavily on external financing, posing sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	5.92M	0.00	0.00	0.00
Gross Profit	5.92M	0.00	0.00	0.00
EBITDA	-74.68M	-68.58M	-55.90M	-39.35M
Net Income	-75.79M	-71.11M	-63.85M	-39.72M
Balance Sheet
Total Assets	305.09M	358.23M	25.92M	28.43M
Cash, Cash Equivalents and Short-Term Investments	285.78M	354.35M	21.64M	27.64M
Total Debt	7.13M	8.70M	53.25M	2.47M
Total Liabilities	27.63M	35.11M	199.32M	140.99M
Stockholders Equity	277.46M	323.13M	-173.40M	-112.56M
Cash Flow
Free Cash Flow	-59.15M	-51.89M	-37.53M	-36.28M
Operating Cash Flow	-58.51M	-51.52M	-37.36M	-36.18M
Investing Cash Flow	-80.81M	-366.00K	-266.00K	-103.00K
Financing Cash Flow	20.36M	381.20M	34.94M	2.50M

BioAge Labs, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOA	59 Neutral	$499.10M	-6.58	-25.64%	―	―	-1.89%
IRWD	58 Neutral	$660.48M	25.78	―	―	-10.42%	―
DERM	57 Neutral	$198.36M	-19.91	-47.05%	―	2.82%	60.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LFCR	48 Neutral	$291.11M	-5.96	―	―	0.47%	-430.88%
IXHL	46 Neutral	$137.80M	-0.37	-114.52%	―	-86.05%	24.17%

BioAge Labs, Inc. Corporate Events

BioAge Labs advances BGE-102 with strong Phase 1 data

On January 12, 2026, BioAge Labs reported additional positive interim Phase 1 data for its lead candidate BGE-102, a brain-penetrant NLRP3 inhibitor in development for patients with elevated cardiovascular risk. In a multiple ascending dose cohort of obese participants with high baseline inflammation, a 120 mg once-daily regimen of BGE-102 achieved an 86% median reduction in hsCRP by Day 14, with 93% of treated participants reaching hsCRP levels below 2 mg/L, a threshold associated with reduced cardiovascular events. The drug also produced meaningful declines in IL-6 and fibrinogen, showed strong IL-1β suppression consistent with robust target engagement, and was reported to be well tolerated, while the company secured a patent covering additional composition of matter and a novel NLRP3 binding site. Building on earlier favorable safety, pharmacokinetic, and brain-penetration data disclosed in December 2025, these results bolster BioAge’s positioning in inflammation-driven cardiovascular disease and support its plan to complete the Phase 1 trial and advance BGE-102 into a roughly 100-patient Phase 2a proof-of-concept study in obesity with cardiovascular risk factors in 2026, with key readouts expected later in the year.

The most recent analyst rating on (BIOA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.

BioAge Labs Announces Positive Phase 1 Trial Results

On December 4, 2025, BioAge Labs announced positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel NLRP3 inhibitor. The trial showed that BGE-102 was well-tolerated and achieved significant suppression of IL-1β, indicating strong target engagement and high brain penetration. The company plans to expand the trial to include participants with obesity and elevated hsCRP, with further data expected in the first half of 2026. These findings support BGE-102’s potential to target inflammation in both the central nervous system and peripheral tissues, positioning BioAge favorably in the biopharmaceutical industry.

The most recent analyst rating on (BIOA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.